Jan Skvarka

CIK: 0001838042

Transaction Breakdown

Open Market Buys (P)1 (20.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ZNTL

Zentalis Pharmaceuticals, Inc.

Director

GLUE

Monte Rosa Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

ZNTL
Zentalis Pharmaceuticals, Inc.
Jun 16, 2026
Award(A)
Direct
57.1K shares-
GLUE
Monte Rosa Therapeutics, Inc.
Jun 11, 2026
Award(A)
Stock Option (Right to Buy)
Direct
25.8K shares-
ZNTL
Zentalis Pharmaceuticals, Inc.
Jun 17, 2025
Award(A)
Direct
57.6K shares-
GLUE
Monte Rosa Therapeutics, Inc.
Jun 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
30.7K shares-
ZNTL
Zentalis Pharmaceuticals, Inc.
Jan 31, 2025
Purchase(P)
Direct
60K shares at avg. $1.72$103K

		Type	Shares	Price		Ownership
Jun 16, 2026	ZNTL Zentalis Pharmaceuticals, Inc.	Award(A)	57,100	-	$0	Direct
Jun 11, 2026	GLUE Monte Rosa Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	25,800	-	-	Direct
Jun 17, 2025	ZNTL Zentalis Pharmaceuticals, Inc.	Award(A)	57,603	-	-	Direct
Jun 13, 2025	GLUE Monte Rosa Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	30,700	-	-	Direct
Jan 31, 2025	ZNTL Zentalis Pharmaceuticals, Inc.	Purchase(P)	60,000	$1.72	$103,446	Direct

1-5 of 5 transactions

About Skvarka Jan

Skvarka Jan (SEC CIK 0001838042) files insider reports with the SEC as Director of Zentalis Pharmaceuticals, Inc. (ZNTL) and Director of Monte Rosa Therapeutics, Inc. (GLUE).

Signal8 holds 5 ownership filings by Skvarka Jan, all Form 4s, filed between Feb 4, 2025 and Jun 18, 2026. Those filings report 5 transactions, from Jan 31, 2025 to Jun 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Skvarka Jan's filings is in BOSTON, MA.

Recent filings by Skvarka Jan

Jun 16, 2026: Grant or award of ZNTL shares (Form 4, code A).
Jun 11, 2026: Grant or award of GLUE derivative securities (Form 4, code A).
Jun 17, 2025: Grant or award of ZNTL shares (Form 4, code A).
Jun 13, 2025: Grant or award of GLUE derivative securities (Form 4, code A).
Jan 31, 2025: Open-market purchase of ZNTL shares (Form 4, code P).

Other insiders filing for Zentalis Pharmaceuticals, Inc. (ZNTL)

Bruns Ingmar, Chief Medical Officer
WALTERS GROUP, 10% Owner
Johnson David Michael, Director
Walker Luke Nathaniel, Director
Kariuki Enoch, Director
Myers Scott Dunseth, Director

How to read Form 4 transaction codes